Floatz logo

Mitoxantrone

Acute Myelomonocytic Leukemia M4

Stanford UniversitySmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Acute Myelomonocytic Leukemia M4 cohort.

Asset / SponsorPhaseRating
Etoposide
Stanford University
Phase 3BBB
Cytarabine
University of Alberta
Phase 3BBB
Daunomycin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
Idarubicin
University of Alberta
Phase 3BBB

View all 50 →

Same molecule, other indications

Mitoxantrone is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative · Phase 4
77 / 100
View asset →
acute monocytic leukemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →
myeloid neoplasmActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →